Celldex (NASDAQ:CLDX) presented Phase 2 data at AAD 2026 showing barzolvolimab produced rapid, profound and durable quality-of-life improvements in chronic spontaneous urticaria (CSU), cold urticaria (ColdU) and symptomatic dermographism (SD).
Key results: up to 51% complete response at Week 12 (CSU), 71% at Week 52, 41% maintained response seven months off therapy; ColdU/SD complete responses reached up to 66% and 49% at Week 20. DLQI domain scores improved across all six domains with many patients achieving DLQI 0/1.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.